SG11201407229UA - Substituted pyrazole compounds as lpar antagonists - Google Patents
Substituted pyrazole compounds as lpar antagonistsInfo
- Publication number
- SG11201407229UA SG11201407229UA SG11201407229UA SG11201407229UA SG11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA SG 11201407229U A SG11201407229U A SG 11201407229UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- pct
- compounds
- designated states
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 241000867614 Mimus polyglottos Species 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661958P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062458 WO2013189862A1 (en) | 2012-06-20 | 2013-06-17 | Substituted pyrazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407229UA true SG11201407229UA (en) | 2014-12-30 |
Family
ID=48656033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407229UA SG11201407229UA (en) | 2012-06-20 | 2013-06-17 | Substituted pyrazole compounds as lpar antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150259295A1 (es) |
| EP (1) | EP2864294A1 (es) |
| JP (1) | JP2015520201A (es) |
| KR (1) | KR20150011003A (es) |
| CN (1) | CN104411690A (es) |
| AU (1) | AU2013279510A1 (es) |
| BR (1) | BR112014031108A2 (es) |
| CA (1) | CA2869602A1 (es) |
| CL (1) | CL2014003242A1 (es) |
| CO (1) | CO7160077A2 (es) |
| CR (1) | CR20140516A (es) |
| EA (1) | EA201492283A1 (es) |
| HK (1) | HK1206341A1 (es) |
| IL (1) | IL236091A0 (es) |
| IN (1) | IN2014DN09347A (es) |
| MA (1) | MA37765A1 (es) |
| MX (1) | MX2014014105A (es) |
| PE (1) | PE20142445A1 (es) |
| PH (1) | PH12014502364A1 (es) |
| SG (1) | SG11201407229UA (es) |
| UA (1) | UA109867C2 (es) |
| WO (1) | WO2013189862A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG2014011555A (en) | 2011-08-15 | 2014-08-28 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| EA033923B1 (ru) | 2013-03-15 | 2019-12-10 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| ES2962367T3 (es) * | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| JP2023529369A (ja) | 2020-06-03 | 2023-07-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CR20220609A (es) | 2020-06-03 | 2023-05-04 | Gilead Sciences Inc | Antagonistas del receptor de lpa y usos de los mismos |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080249154A1 (en) * | 2003-12-26 | 2008-10-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| WO2011017350A2 (en) * | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| MX2013006040A (es) * | 2010-12-07 | 2013-08-26 | Amira Pharmaceuticals Inc | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| SG2014011555A (en) * | 2011-08-15 | 2014-08-28 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
-
2013
- 2013-06-17 BR BR112014031108A patent/BR112014031108A2/pt not_active Application Discontinuation
- 2013-06-17 IN IN9347DEN2014 patent/IN2014DN09347A/en unknown
- 2013-06-17 MA MA37765A patent/MA37765A1/fr unknown
- 2013-06-17 WO PCT/EP2013/062458 patent/WO2013189862A1/en active Application Filing
- 2013-06-17 CA CA2869602A patent/CA2869602A1/en not_active Abandoned
- 2013-06-17 JP JP2015517702A patent/JP2015520201A/ja active Pending
- 2013-06-17 EA EA201492283A patent/EA201492283A1/ru unknown
- 2013-06-17 UA UAA201500427A patent/UA109867C2/ru unknown
- 2013-06-17 PE PE2014002212A patent/PE20142445A1/es not_active Application Discontinuation
- 2013-06-17 SG SG11201407229UA patent/SG11201407229UA/en unknown
- 2013-06-17 MX MX2014014105A patent/MX2014014105A/es unknown
- 2013-06-17 CN CN201380032266.8A patent/CN104411690A/zh active Pending
- 2013-06-17 EP EP13729940.0A patent/EP2864294A1/en not_active Withdrawn
- 2013-06-17 US US14/402,128 patent/US20150259295A1/en not_active Abandoned
- 2013-06-17 AU AU2013279510A patent/AU2013279510A1/en not_active Abandoned
- 2013-06-17 KR KR1020147035552A patent/KR20150011003A/ko not_active Application Discontinuation
-
2014
- 2014-10-22 PH PH12014502364A patent/PH12014502364A1/en unknown
- 2014-11-11 CR CR20140516A patent/CR20140516A/es unknown
- 2014-11-28 CL CL2014003242A patent/CL2014003242A1/es unknown
- 2014-12-04 IL IL236091A patent/IL236091A0/en unknown
- 2014-12-19 CO CO14279332A patent/CO7160077A2/es unknown
-
2015
- 2015-07-21 HK HK15106926.9A patent/HK1206341A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2864294A1 (en) | 2015-04-29 |
| EA201492283A1 (ru) | 2015-04-30 |
| PE20142445A1 (es) | 2015-01-28 |
| JP2015520201A (ja) | 2015-07-16 |
| PH12014502364A1 (en) | 2015-01-12 |
| IL236091A0 (en) | 2015-02-01 |
| US20150259295A1 (en) | 2015-09-17 |
| CL2014003242A1 (es) | 2015-03-20 |
| MX2014014105A (es) | 2015-03-05 |
| CA2869602A1 (en) | 2013-12-27 |
| CR20140516A (es) | 2014-12-01 |
| CO7160077A2 (es) | 2015-01-15 |
| KR20150011003A (ko) | 2015-01-29 |
| WO2013189862A1 (en) | 2013-12-27 |
| MA37765A1 (fr) | 2017-04-28 |
| HK1206341A1 (en) | 2016-01-08 |
| UA109867C2 (ru) | 2015-10-12 |
| CN104411690A (zh) | 2015-03-11 |
| AU2013279510A1 (en) | 2014-10-16 |
| BR112014031108A2 (pt) | 2017-06-27 |
| IN2014DN09347A (es) | 2015-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408238WA (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |